Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-29 | Dennis H. Langer, M.D., J.D. was appointed as a Director in December 2014. ... The current members of the Audit Committee are: William D. Rueckert (Chair), Dennis H. Langer and Laura A. Philips, each of whom is "independent" within the meaning of the NASDAQ listing rules and otherwise meet the financial statement proficiency requirements of the NASDAQ listing rules. ... The current members of the Compensation and Stock Option Committee are Laura A. Philips (Chair), Dennis H. Langer and Marco Taglietti, each of whom is "independent" within the meaning of the NASDAQ listing rules. ... The following table sets forth the compensation awarded to, earned by or paid to each director who served on our Board of Directors in 2014. ... Dennis H. Langer, M.D. J.D. Fees Earned or Paid in Cash: 3,148; Stock Awards: 0; Options Awards: 25,993; All Other Compensation: 0; Total: 29,141. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-15 | Dennis H. Langer, M.D., J.D. (1) (3) 61 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2013 to each of our non-employee directors who served during fiscal 2013. ... Dennis H. Langer, M.D., J.D. Fees Earned or Paid in Cash ($) 93,000 Option Awards ($) 304,854 Total ($) 397,854 |
| 2014-10-14 | Dennis H. Langer, M.D., J.D. (1) (3) 62 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2014 to each of our non-employee directors who served during fiscal 2014. Dennis H. Langer, M.D., J.D. Fees Earned or Paid in Cash ($) 93,000 Option Awards ($) 290,517 Total ($) 379,517 |
| 2015-10-15 | Dennis H. Langer, M.D., J.D. (1) (3) 63 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2015 to each of our nonemployee directors who served during fiscal 2015. ... Dennis H. Langer, M.D., J.D. 88,500 346,800 435,300 |
| 2016-10-11 | Dennis H. Langer, M.D., J.D. (1)(3) 64 Director ... (1) Member of the Audit Committee. (3) Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2016 to each of our nonemployee directors who served during fiscal 2016. Dennis H. Langer, M.D., J.D. 90,500 Fees Earned or Paid in Cash ($) 318,525 Restricted Stock Unit Awards ($) 409,025 Total ($) |
| 2017-10-12 | Dennis H. Langer, M.D., J.D., has been a director of Myriad since May 2004. ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee. ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2017 to each of our nonemployee directors who served during fiscal year 2017. ... Dennis H. Langer, M.D., J.D. ... 90,500 Fees Earned or Paid in Cash, 250,000 Restricted Stock Unit Awards, 340,500 Total. |
| 2018-10-10 | Dennis H. Langer, M.D., J.D. (1) (3) 66 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2018 to each of our nonemployee directors ... Dennis H. Langer, M.D., J.D. 340,494 |
| 2019-10-16 | Dennis H. Langer, M.D., J.D. (1) (3) 67 Director ... Member of the Audit Committee. ... Member of the Nominating and Governance Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2019 to each of our nonemployee directors ... Dennis H. Langer, M.D., J.D. 92,500 Fees Earned or Paid in Cash, 299,988 Restricted Stock Unit Awards, 392,488 Total. |
| 2020-10-15 | Dennis H. Langer, M.D., J.D., has been a Director of Myriad since May 2004... The Nominating and Governance Committee currently has four members: Dr. Langer (chair), Dr. Henderson, Ms. Phanstiel, and Ms. Reitan... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2020 to each of our nonemployee directors... Dennis H. Langer, M.D., J.D. 88,438 300,005 388,443 |
| 2021-04-15 | Dennis H. Langer, M.D., J.D., has been a Director of Myriad since May 2004... Age: 69... Committees: Compensation and Human Capital Committee (Chair)... Director Compensation Table: Dennis H. Langer Fees Earned or Paid in Cash: 60,250, Stock Awards: 299,984, Total: 360,234. |
| 2022-04-14 | Dennis H. Langer, M.D., J.D., has been a Director of Myriad since May 2004. Dr. Langer has served as a Director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies, including Chairman and Chief Executive Officer of AdvanDx, Inc. (2013-2014), Managing Partner of Phoenix IP Ventures, LLC (2005-2010), President, North America for Dr. Reddy’s Laboratories, Inc. (2004-2005), a Senior Vice President, R&D at GlaxoSmithKline and SmithKline Beecham (1994-2004), and Chief Executive Officer, Neose Technologies, Inc. (1991-1994). Dr. Langer also serves as a Director of Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) and Quoin Pharmaceuticals, Ltd. (Nasdaq: QNRX), and during the past five years he served as a Director of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) and Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX). Previously, Dr. Langer held R&D and marketing positions at Lilly, Abbott and Searle. Dr. Langer is a Clinical Professor, Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. The Board of Directors has determined that Dr. Langer should serve on the Board for the following reasons: He provides the Board with important expertise in developing predictive, personalized and prognostic testing products, as well as experience in research and development which is critical to our development of molecular diagnostic testing services. As a board-certified psychiatrist with extensive experience in neuropsychiatric drug development, Dr. Langer provides the Board with expertise in developing and commercializing diagnostics for patients suffering from neuropsychiatric and other related conditions. Additionally, he provides management expertise from serving on several public company boards in the healthcare industry. Age:70 Director Since:2004 Committees: Audit and Finance Committee, Nominating, Environmental, Social and Governance Committee |
Data sourced from SEC filings. Last updated: 2026-02-03